Pipeline
We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.
Cancer Supportive Care
Fosnetupitant
Single agent CINV1 in U.S.
Fosnetupitant - Palonosetron
Pediatric CINV1
Fosnetupitant - Palonosetron IV
IV - China - CINV1,2
Anamorelin3
Global - Cancer Anorexia-Cachexia in NSCLC4 patients
Other
HM04
Ghrelin Receptor Antagonist - Prader-Willi Syndrome - Open for partnering
HM01
Ghrelin Receptor Agonist - Partnered
Notes
The safety and efficacy of the agents identified for the investigational uses have not been established: these agents have not been approved for commercial use by any regulatory authority worldwide, except where noted. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.
1. Chemotherapy-Induced Nausea and Vomiting
2. Approved in multiple territories, including USA and EU
3. Approved in Japan
4. Non-Small Cell Lung Cancer